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We have examined the transcriptional changes associated with differentiation from villous to extra-
villous trophoblast using a whole genome microarray. Villous trophoblast (VT) is in contact with
maternal blood and mediates nutrient exchange whereas extravillous trophoblast (EVT) invades the
decidua and remodels uterine arteries. Using highly puriﬁed ﬁrst trimester trophoblast we identiﬁed
over 3000 transcripts that are differentially expressed. Many of these transcripts represent novel func-
tions and pathways that show co-ordinated up-regulation in VT or EVT. In addition we identify new
players in established functions such as migration, immune modulation and cytokine or angiogenic
factor secretion by EVT. The transition from VT to EVT is also characterised by alterations in transcription
factors such as STAT4 and IRF9, which may co-ordinate these changes. Transcripts encoding several
members of the immunoglobulin-superfamily, which are normally expressed on leukocytes, were highly
transcribed in EVT but not expressed as protein, indicating speciﬁc control of translation in EVT. Inter-
actions of trophoblast with decidual leukocytes are involved in regulating EVT invasion. We show that
decidual T-cells, macrophages and NK cells express the inhibitory collagen receptor LAIR-1 and that EVT
secrete LAIR-2, which can block this interaction. This represents a new mechanism by which EVT can
modulate leukocyte function in the decidua. Since LAIR-2 is detectable in the urine of pregnant, but not
non-pregnant women, trophoblast-derived LAIR-2 may also have systemic effects during pregnancy.
 2010 Elsevier Ltd.  Open access under CC BY license.1. Introduction
In the early weeks of human pregnancy the embryo implants
completely into the uterine wall, surrounded by trophoblast cells.
Trophoblast progenitors located at the basement membrane of the
placental villi differentiate into distinct lineages with specialized
functions [1]. Villous trophoblast (VT) cells proliferate and cover
the mesenchyme and fetal vessels that form the placental villous
tree. Subsequent fusion of VT generates an overlying syncytium of
villous syncytiotrophoblast, which provides a large surface area for
nutrient and gas exchange as well as synthesis of hormones such as
progesterone. A distinct lineage of extravillous trophoblast (EVT)travillous trophoblast; uNK,
: þ44 1223 333346.
 BY license.cells arises from VT cells in trophoblast columns at the tip of villi
anchoring the placenta to the uterine wall. EVT do not divide but,
during the ﬁrst trimester of pregnancy, they detach from the
placental villi and invade directly through the decidual stroma as
individual cells. These interstitial EVT can penetrate as far as the
inner third of the myometrium before forming sessile, multinu-
cleated giant cells. Endovascular EVT advance along the luminal
endothelium of decidual spiral arteries, against the direction of
ﬂow. EVT invasion is associated with dramatic remodeling of
decidual spiral arteries. Interstitial EVT destroy the muscular coat
and endovascular EVT displace endothelial cells. Together these
trophoblast cells convert the spiral arteries into distensible low-
resistance channels to increase blood ﬂow to the growing feto-
placental unit. Failure to transform arteries is associated with poor
trophoblast invasion and results in inadequate placental perfusion
[2]. Clinically, this may present as pre-eclampsia, fetal growth
restriction or recurrent miscarriage. Understanding the factors
controlling the differentiation of VT to EVT and the extent of EVT
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management of these complications of pregnancy.
The factors that control exit of VT from the cell cycle, differen-
tiation into motile EVT and the extent of migration are unclear. The
spontaneous differentiation of VT to EVT cells when cultured in
vitro, strongly suggests that this process is largely controlled by an
intrinsic differentiation program. However, interactions with
extracellular matrix (ECM), growth factors secreted by cells in the
decidua and even oxygen tension also inﬂuence trophoblast
differentiation [3]. Differentiation of VT to EVT is accompanied by
complex changes in phenotype that include the expression of
adhesion molecules, such as integrins, metalloproteases and
cathepsins which permit EVT migration. Conversely, decidual cells
express tissue inhibitors of metalloproteinases (TIMPs) and plas-
minogen activator inhibitor (PAI) which function to limit invasion.
How these interactions are co-ordinated has until recently been
unclear. There is now strong evidence that uterine NK (uNK) cells,
the dominant lymphocyte in the decidua during early pregnancy,
also play a role in regulating trophoblast invasion and vascular
conversion [4]. Unlike VT, which lack surface HLA class I or class II,
migrating EVT express a unique repertoire of HLA class I: HLA-C,
HLA-E and HLA-G. Corresponding receptors for these molecules are
present on uNK cells and decidual macrophages at the implantation
site [2]. Immunogenetic data suggests that certain combinations of
genes from the Killer Immunogobulin-like Receptor (KIR) family
expressed on maternal uNK cells and their HLA-C ligands on
trophoblast, are associated with an increased risk of pre-eclampsia
or recurrent miscarriage [5,6]. Although recognition of trophoblast
MHC by receptors such as KIR, LILR and NKG2/CD94 on uNK cells is
clearly important, activating and inhibitory receptors that recog-
nise non-MHC self molecules also regulate NK cell functions and
cytokine secretion. NK cells integrate the signals from receptors for
MHC and non-MHC ligands and responses stimulated by non-MHC
receptors can modify those induced by the conventional MHC
receptors. Over 30 potential receptor/ligand pairs have been
described and uNK cells have been shown to express many of these
[7,8]. Understanding of their role in trophoblast/uNK interactions is
limited because a systematic screen for known and novel ligands
expressed by EVT, has not yet been undertaken.
Efforts to deﬁne how VT to EVT differentiation and subsequent
migration is controlled have also been hampered by the difﬁculty in
obtaining primary VTand EVTcells from the ﬁrst trimester. Herewe
present a microarray analysis of the transcriptome in primary VT
and EVT cells, isolated from healthy ﬁrst trimester pregnancies to
a high degree of purity. The aim of this whole genome analysis was
to deﬁne what transcriptional changes underlie the transition from
the villous to the extravillous phenotype. We also examined the
expression by trophoblast of potential ligands for receptors on NK
cells and other decidual leukocytes to better understand the
interactions between EVT and the maternal immune system.
Microarrays of the JAR and JEG-3 choriocarcinoma cell lines are also
included, to characterise the validity of these models for VT and
EVT, since they are frequently used due to the inaccessibility of
primary trophoblast cells.
2. Methods
2.1. Clinical samples and cell lines
Decidual and placental tissues were obtained from elective terminations of
normal pregnancies between 8 and 12 weeks gestation. Ethical approval for the use
of these tissues was obtained from the Cambridge Local Research Ethics Committee.
For histological staining, blocks of tissue were frozen and 5 mm serial sections cut
before ﬁxing in acetone and storage at 20 C. For ﬂow cytometry, single cell
preparations of trophoblast or leukocytes were isolated as previously described [9].
Brieﬂy, placental villi were identiﬁed macroscopically, digested with trypsin and
collected by density gradient to obtain cells which are 50e80% EGF-Rþ. VT is theonly cell type at the implantation site that expresses EGF-R [10]. EGF-Rþ cells rep-
resenting VT were obtained at high purity by staining these trophoblast cells
immediately, followed by ﬂow cytometry sorting. Alternatively, the primary
trophoblast cells were cultured for 12 h on ﬁbronectin in Hams F12 with 20% fetal
calf serum, after which 50e80% of the cells express HLA-G, a marker speciﬁc for EVT
[9,11]. The resulting HLA-G positive EVT cells were then analysed or puriﬁed by ﬂow
cytometry as described below. Leukocytes were isolated by collagenase digestion of
maternal decidual tissue and stained for ﬂow cytometry immediately. Villous
mesenchyme or decidual stromal cells were obtained by at least 4 passages of the
adherent placental or decidual cells isolated. Peripheral blood leukocytes were
isolated on Lymphoprep (Axis-Shield) from fresh venous blood of normal adult
volunteers. Urine was obtained with informed consent from healthy local donors
who were not pregnant, or throughout gestation, and were stored at 20 C until
use. Urine from pre-eclamptic subjects was provided by the Pregnancy Exposures
and Preeclampsia Prevention (PEPP) study fromwomen at 10 weeks gestation (11 of
whomwent on to develop pre-eclampsia and 11 healthy controls) and by the SCOPE
project from women at 15(1) weeks gestation (20 of whom went on to develop
pre-eclampsia and 20 healthy controls). Both studies were approved by Ethical
Board review. JAR and JEG-3 cells were purchased from the American Type Culture
Collection and cultured according to their instructions (ATCC reference numbers
HTB-144 and HTB-36).2.2. Monoclonal antibodies
Monoclonal antibodies (mAbs) used which bind HLA-G were G233 [12] made in
our own laboratory and MEM-G/9-FITC [13] from Serotec. Additional unconjugated
mAbs were to IL-15Ra (clone JM7A4) from BioLegend, cytokeratin (clone PKK-1)
from Labsystems, IL-2Rb (clone TU27) from Prof. K. Sugamura and LAIR-2 (clone
FMU-LAIR 2.1) from Dr. Boquan Jin. Conjugated mAb purchased were EGF-R-FITC
(clone EGF-R1) from Insight Biotechnologyl; HLA-DR-FITC (clone L243), CD56-Alexa
Fluor 488 (clone B159), CD3-FITC (clone SK7), CD14-PE (clone M4P9), CD132-PE
(clone AG184) and LAIR-1-PE (clone DX26) all from Becton Dickinson; LILRB1-PE
(clone HP-F1) from Beckman Coulter; LILRB3-PE (clone 293623) from R&D Systems;
CD45-PE-Cy5 (clone HI30) and IL-2Rb-APC (clone TU27) both from BioLegend. Iso-
type controls used were the mAbs HIB19 and X40 (unconjugated and PE-conju-
gated) from Becton Dickinson, MOPC-21-APC from Biolegend and 20102-PE from
R&D. Where indicated, binding of unlabelled mAbs was detected by polyclonal
PE-conjugated secondary antibody to murine IgG (SigmaeAldrich). Biotinylated
polyclonal goat anti-LAIR-2 IgG was also obtained from R&D Systems.2.3. Flow cytometry
Freshly isolated cells or those harvested by trypsin digestion of adherent
trophoblast after overnight culture were resuspended in FACS buffer (1% FCS in
PBS), incubated with human IgG (SigmaeAldrich) followed by unlabelled primary
monoclonal antibodies and then ﬂuorochrome-conjugated polyclonal secondary
antibodies. Free secondary antibody binding sites were blocked with murine
immunoglobulin (SigmaeAldrich) before staining with directly-conjugated mAb to
identify leukocyte or trophoblast cell populations. Cells were analysed using
FACScan or FACSCalibur ﬂow cytometers with CellQuest software (Becton Dick-
inson), or sorted using a DakoCytomation MoFlo cytometer and Summit software.2.4. Expression proﬁling by microarray
2.4.1. RNA preparation
Total RNA was isolated from primary trophoblast or choriocarcinoma cell lines
by lysis in Trizol (Invitrogen) followed by cleanup and DNAse treatment using
RNeasy Micro kits (Qiagen). Biotinylated cRNA was synthesized using 100 ng of this
total RNA using the Illumina RNA ampliﬁcation kit (Ambion) according to the
manufacturer’s instructions.
2.4.2. Array hybridization
Labelled cRNA was hybridised to Illumina Human HT-12 V3 BeadArrays using
the manufacturer’s standard protocol (http://www.illumina.com/). Illumina Bead-
Studio output, comprising background corrected and summarised expression scores
for each microarray probe-set, was imported using functions of the BeadArray
package for the Bioconductor (http://bioconductor.org) suite of software in the R
statistical programming environment (http://www.r-project.org).
2.4.3. Data processing
Signal intensities were converted to log2 expression units. Quantile normal-
isation [14], implemented in the limma package for Bioconductor, was employed to
equalise summarised expression intensity distributions across all sample proﬁles.
Probe-sets were annotated to gene targets using annotations from the illuminaHu-
manv3.db package for Bioconductor and themanufacturer’s own annotation package.
Raw and processed data are available from the ArrayExpress microarray data repos-
itory (http://www.ebi.ac.uk/arrayexpress/) under accession number E-MTAB-429.
Fig. 1. Comparison of gene expression proﬁles in primary EVT and VT with the chorio-
carcinoma cell lines JEG-3 and JAR. Unsupervised hierarchical clustering of the four cell
types was performed using transcripts identiﬁed as showing variable expression across
all samples (A).Organisation and lengthof thedendrogrambranches reﬂect thedegreeof
similarity between samples. (B). Identiﬁcation of speciﬁc transcripts which differ
signiﬁcantly in expression (q<0.01) byat least 4-fold upordownbetweencell types. 885
transcripts differ betweenEVTandVTby these criteria, comparedwith only 183 between
JEG and JAR. 1188 transcripts differ between EVT and JEG and 870 between VT and JAR
respectively. (C). The differences in expressionbetweenEVTandVTcells arenot the same
as the differences between JEG and JAR. For example, of the 457 transcripts at least 4-fold
lower in EVT compared with VT, only 3 of these transcripts are also lower in JEG vs JAR.
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Differential probe-set (or gene) expression between two sample groups was
assessed via the output of a moderated t-test ([15], Bioconductor:limma). In order to
reduce errors associated with multiple hypothesis testing on such a scale, the
signiﬁcance p-values obtained were converted to corrected q-values using the FDR
method of Storey et al [16]. Probe-sets with associated q < 0.01 (FDR 1%) were
deemed to exhibit signiﬁcant differential expression between sample groups.
2.4.5. Over-representation analysis
The statistical over-representation of Gene Ontology (GO; http://www.
geneontology.org) Biological Process categories and Kyoto Encyclopoedia of Gene
and Genomes pathways (KEGG; http://www.genome.jp/kegg) among genes deemed
differentially expressed between sample group proﬁles was assessed via the
hypergeometric statistics of the GOStats package for Bioconductor.
2.4.6. Data Visualisation
Gene products within KEGG pathway maps were coloured according to up- or
down-regulation of corresponding microarray probe-sets using the Color Pathway
tool available via the KEGG website (http://www.genome.jp/kegg/tool/color_pathway.
html).
2.5. Immunohistochemistry
Immunohistochemistry was performed as previously described [17]. Brieﬂy,
acetone-ﬁxed frozen sections were blocked with serum of the species in which the
secondary antibody was raised before staining with the antibodies described above.
Binding was detected by biotinylated secondary antibodies followed by streptavi-
din-HRP (both Vector Labs) and developed with DAB substrate (SigmaeAldrich).
Slides were counterstained with Carazzi’s haematoxylin, cleared in xylene and
mounted in DPX.
2.6. Sandwich enzyme-linked Immunosorbant assay (ELISA)
An ELISA for LAIR-2 was performed as previously described [18]. Brieﬂy, urine
samples or trophoblast culture supernatant were stored at 20 C before analysis
using the capture mAb FMU-LAIR 2.1 and detecting with puriﬁed biotinylated
puriﬁed polyclonal antibody from R&D systems. Creatinine was measured using
a commercial version of the Jaffe reaction (Assay Designs) to normalize for urine
sample concentration. Despite changes in glomerular ﬁltration rate, creatinine levels
are constant throughout gestation in normal pregnancies [19] and we observed no
differences in creatinine between urine from pregnant and non-pregnant women
(not shown).
3. Results
3.1. Isolation of pure villous and extravillous trophoblast cells for
analysis by microarray
The cells released from chorionic villi after a short trypsin digest
are predominantly VT and these were puriﬁed immediately to
>99% by ﬂow sorting of EGFRþcells (Suppl Fig. 1). If villous cell
isolates are instead cultured overnight on ﬁbronectin, the adherent
cells are mainly EVT and by ﬂow sorting for HLA-Gþcells, EVT of
>99% purity were obtained (Suppl Fig. 1). Hofbauer cells (fetal
macrophages) were positively excluded by labelling for CD14 or
HLA-DR in both procedures, because they bind the mAbs used for
trophoblast labelling via FcgR. Three separate preparations of VT
and three of EVT were isolated from a total of six independent
pregnancies. Choriocarcinoma cell lines JEG-3 and JAR cultured in
vitro were also harvested on three different occasions. The twelve
RNA samples isolated from these four cell types, were then hybri-
dised independently to microarrays as described in the Materials
and Methods.
3.2. Comparison of choriocarcinoma cell lines to primary
trophoblast
JEG-3 expresses HLA-G, while JAR is HLA class I negative. Based
on this phenotype, these choriocarcinoma cell lines arewidely used
as models of primary EVT and VT respectively. The expression
proﬁles of primary EVT and VT cells were compared with the cor-
responding cell lines JEG-3 and JAR. Unsupervised hierarchical
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individual groups, indicating a distinctive expression proﬁle, but
the two choriocarcinoma lines clustered together on a separate
branch from either primary cell type (Fig. 1A). Over 850 transcripts
differed signiﬁcantly (q < 0.01) by at least 4-fold between EVT and
VT, EVT and JEG-3, VT and JAR; whereas only 183 transcripts
differed between JEG and JAR (Fig. 1B). Although HLA-G was up-
regulated in both EVT and JEG-3 compared VT and JAR, the genes
differentially expressed between the two lineages of primary
trophoblast were not represented by those transcripts differing
between the JEG-3 and JAR cell lines (Fig. 1C). Indeed, more tran-
scripts differ between EVT and the ‘corresponding’ cell line JEG-3
than between EVT and VT. These choriocarcinoma cell lines appear,
at the transcriptional level, to be poorly representative of the cor-
responding VT and EVT.
3.3. Comparison of EVT and VT
Comparison of the expression proﬁles of EVT and VT identiﬁed
3471 probes with q < 0.01 (FDR 1%) indicating differential
expression. When classiﬁed into functional categories based on
either GO annotation or KEGG pathways, over-representation
analysis revealed that the most signiﬁcantly up-regulated GO bio-
logical processes in EVT included ‘cell motion’ (63 transcripts),
‘immune response’ (71 transcripts) and ‘leukocyte adhesion’ (7
transcripts) (p < 0.0025, Supplementary Table 1). The most
signiﬁcantly down-regulated processes in EVT included metabolic
processes such as ‘lipid metabolism’ and ‘fatty acid oxidation’ as
well as ‘negative regulators of cell differentiation’. Speciﬁc func-
tions represented by these transcripts were identiﬁed using the
KEGG pathways which include known functional relationshipsFig. 2. The Focal Adhesion Kinase (FAK) KEGG pathway has a signiﬁcant number of transcript
regulated in EVT are coloured red, transcripts that are signﬁcantly lower in EVT comparedbetween transcripts. Signiﬁcantly up-regulated (p < 0.01) KEGG
pathways included focal adhesion, extracellular matrix (ECM)
receptor interactions, leukocyte transendothelial migration and
cancer, whereas down-regulated pathways included amino acid
metabolism, fatty acid metabolism and biosynthesis of steroids
(Supplementary Table 2). These results show that as VT differen-
tiate to EVT, there is co-ordinated up and down-regulation of
speciﬁc pathways. The very signiﬁcant up-regulation of more than
40 transcripts involved in the focal adhesion kinase (FAK) and ECM-
receptor pathways, which are linked through the integrin recep-
tors, clearly identiﬁes a potentially important role for the focal
adhesion kinase (PTK2) (Fig. 2). Several members of this pathway
that are involved in cell proliferation are down-regulated on
differentiation to EVT (VAV, JUN and CYCD). The FAK pathway also
integrates transcripts involved in transducing signals that enhance
cell migration (PAK, MLC, ACTN4), and these are up-regulated in
EVT. Thus, this pathway offers novel insights into how FAKmight be
involved in the transition from proliferation in VT to post-mitotic,
migratory EVT. Even in functions that have been well studied, such
as migration, or ECM/receptor interactions we provide novel and
more detailed information regarding the speciﬁc transcriptional
changes underlying known differences in trophoblast function
(Suppl Table 4).
3.4. Analysis of speciﬁc genes detected in EVT and VT
Of the 3471 probes differing signiﬁcantly between EVTand VT (q
< 0.01), 885 transcripts differed bymore than 4-fold (listed in Suppl
Table 3). A selection of these transcripts, classiﬁed into functional
catagories based on gene ontology annotations is presented in
Fig. 3. The genes most strikingly up-regulated in VT were solutes up-regulated in EVT vs VT (p< 0.01). Individual transcripts signiﬁcantly (q < 0.01) up-
to VT are coloured blue. Green indicates no signiﬁcant change.
Fig. 3. Genes differentially expressed between EVT and VT. A mean hybridization signal is used for each transcript, with all differences signiﬁcant at q < 0.01. Only selected genes are shown here, for a complete list see Suppl Table 3.
Genes were classiﬁed into functional categories based on Gene Ontology annotations.
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Fig. 4. The IL-2 receptor b subunit is up-regulated on trophoblast cells as they
differentiate from villous to extravillous phenotype. Upregulation of IL-2Rb expression
was validated by ﬂow cytometry (AeC) and immunohistochemistry (D). Preparations
of placental cells from normal ﬁrst trimester pregnancies were gated on scatter,
leukocytes excluded by CD45 labelling (gate R2) and subunits of the IL-15 receptor
complex stained on villous (EGF-Rþ) or extravillous (HLA-Gþ) trophoblast cells (A).
Dot plots are shown of IL-2Rb subunit staining villous (B) and extravillous trophoblast
(C). Shown here are cells from the same placenta which is representative of 3 preg-
nancies analysed. The IL-2Rb was also localised histologically in sections of implan-
tation site from the ﬁrst trimester (D). The low power plan stained with cytokeratin
shows villous mesenchyme (top left) and a column of EVT (bottom right) developing
from placental villi (centre). Higher power pictures show strong IL-2Rb staining
detected on extravillous trophoblast migrating away from the villi, whereas staining
was negligible on villous trophoblast and villous mesenchymal cells.
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SLC22A11 > 130-fold and another 5 members of this family were
expressed at levels more than 10-fold higher than in EVT. Also
strongly up-regulated in VT were imprinted genes, PEG3 and PEG10
(>50-fold), the adhesion molecules integrin b5, siglec 6 and FRAS1
(>30-fold), human endogenous retroviruses HERV-FRD and
ERVWE1, the transcription factor ELF5 and receptors for soluble
factors such as colony stimulating factor 3, ephrin receptor, EPHB4
and growth hormone receptor (all around 20-fold). Also strongly
up-regulated in VT were poorly-characterised molecules such as
palmitylated membrane protein 1 (MPP1) and contactin-associated
protein-like 2 (CNTNAP2), both 40-fold higher in VT; lipoprotein
receptor-related 5 (LRP5), the G-protein coupled receptors, GPR56
and GPR172B (all around 30-fold) and the Ig-domain receptor,
ILDR1 (10-fold). Many of these represent transcripts not previously
known to be highly expressed in VT.
The list of genes highly up-regulated in EVT compared to VT,
contains many involved in immune function (Fig. 3). HLA-G along
with the peptide loading chaperones TAP1þ2, as well as LAIR-2,
complement factor B (CFB) and the recently identiﬁed NK ligand
PVR (CD155) are all up-regulated by at least 20-fold. Cytokine/
chemokine receptors such as CCR1, IL-1R2, IL-1RAP, IL-2RB, TNF-
RSF25, ACVRL1 and ACVR1B are all increased, suggesting EVT
acquires an enhanced ability to respond to the wide range of
cytokines secreted in the decidua. Many cytokine-responsive
factors are indeed increased including interferon-inducible
proteins such as IFITM2, IFIT1 and IFI27 which is 100-fold higher in
EVT. A second category of genes signiﬁcantly up-regulated in EVT
includes transcripts concerned with the regulation of cell migra-
tion: extracellular matrix proteases such as PAPPA (84-fold), ADAM-
19 (64-fold), laeverin (AQPEP) and TIMP2 (both 30-fold) as well as
SERPINE2 which has the third highest expression level of all tran-
scripts in EVT. Adhesion molecules that regulate cell migration are
also up-regulated in EVT, including integrins a-1, -2 and -5 (w25-
fold), while integrins b-4 and b-5 are down-regulated as described
previously [20]. We have also identiﬁed novel adhesion molecules
not previously reported to be up-regulated on EVT: endothelial cell-
speciﬁc adhesion molecule ESAM (55-fold higher in EVT) and
vascular endothelial junction-associated molecule JAM2 (16 fold).
Both molecules are involved in regulating the adhesion of leuko-
cytes to endothelium, and their up-regulation by EVT suggests
trophoblast may utilize these molecules to interact with decidual
leukocytes [21]. Different sets of solute carriers to those found in VT
are up-regulated: SLCO2A1 is over 100-fold higher in EVT and
SLC7A1, KCNK12 and FXYD5 are all up 20-fold. These may reﬂect
new transport requirements to support changes in metabolic and
synthesis requirements between VT and EVT. Other genes were the
transcription factor STAT4, the glypican G (both >50-fold) and the
anthrax toxin receptor ANTXR1 (25-fold). Also strongly up-regu-
lated in EVT were less well characterised molecules such as small
proline-rich protein 2G (SPRR2G), 85-fold higher in EVT; MAMDC2
(55-fold), and the G-protein coupled receptor GPR116 (>30-fold).
Two critical functions of EVT are their role in blood vessel
remodeling and their interactions with maternal immune cells in
the decidua. It is striking that transcripts encoding several novel
growth factors previously unknown to be secreted by trophoblast
are highly up-regulated in EVT. These included gastrokine 1 (GKN1),
the neurosecretory protein VGF and CXCL16, whose receptor CXCR6
is also up-regulated in EVT by 3.7 fold. TGFB2 and the corre-
sponding receptors TGFBR2 and ACVRL1 were also highly up-regu-
lated, again indicating co-ordinated regulation of this pathway
leading to a potential autocrine loop in EVT. Several of these growth
factors are potent regulators of angiogenesis. Connective tissue
growth factor (CTGF) and placental growth factor (PGF) promote
endothelial cell migration and proliferation, potently regulating
Fig. 5. Extravillous trophoblast cells secrete LAIR-2. In histological staining of a ﬁrst trimester implantation site extravillous trophoblast (arrowed) differentiating from a placental
villus stain for LAIR-2 but not isotype control mAb (A). This secreted LAIR-2 can be detected by ELISA. LAIR-2 is detected in culture supernatant of extravillous trophoblast but not
other placental or decidual cells from the implantation site of normal ﬁrst trimester pregnancies (B). LAIR-2 in the urine of 23 pregnant women between 25 and 45 weeks gestation,
but not non-pregnant women (C). Analysis of urine from two women throughout gestation shows LAIR-2 levels are highest before 20 weeks (D). No signiﬁcant difference was found
in urine LAIR-2 levels collected at 10e16 weeks gestation, from women who subsequently developed pre-eclampsia or who had pregnancies without complications (Man-
neWhitney U test) (E). Filled circles are 14e16 week samples, open circles were collected at 10 weeks. There was no signiﬁcant difference between samples from different
timepoints, so the data was combined.
R. Apps et al. / Placenta 32 (2011) 33e43 39angiogenesis and extracellular remodeling through their interac-
tions with VEGF [22]. In contrast endothelial cell-speciﬁc growth
factor (ECGF) promotes angiogenesis by a novel mechanism, in
which the conversion of thymidine to thymine generates sugars
such as 2-Deoxy-D-ribose which locally promote endothelial cell
chemotaxis [23].
Genes highly expressed in both VT and EVT were also analysed.
Transcripts encoding ribosomal, cellular organelle and cytoskeleton
proteins as well as collagens and proﬁlins were ﬁrst excluded since
these are abundant in all cells. A selection of other highly expressed
genes identifying aproﬁle characteristic of bothVTandEVT is shown
in Suppl Fig. 2. Transporters for calcium (TPT1), iron (FTL), glucose
(SLC2A1), choline (SLC44A4) and other solutes are well represented
(S100P, KCNH6, DIRC2, CLDND1). Several genes involved in amyloid
processing appear: ITM2B, BRI3, TMEM147. Adrenomedullin (ADM),
differentiation marker MYADM, the thrombin and putative proges-
terone receptors (F2R and PGRMC2) and imprinted genes (H19 and
CD81) are all detected at particularly high levels. Molecules with
immune-related functions such as cytokine and chemokine recep-
tors were prominent. A surprise ﬁnding was that the immuno-
globulin and lectin family receptors LAIR1, LILRB1, LILRB3 andCLEC2D
were highly expressed in trophoblast, LAIR1 being in the top 25 of all
transcripts in both VT and EVT (Suppl Fig. 2).
3.5. Protein expression of LILRB1, LILRB3 and LAIR-1 is not detected
on trophoblast cells
Leukocyte receptor complex genes LILRB1, LILRB3 and LAIR-1 are
typically expressed on leukocytes and are all important inregulation of NK cell function [7]. We examined expression of these
genes at the protein level, but no surface expression on trophoblast
cells was observed by ﬂow cytometry (Suppl Fig. 3A, B). Fetal
Hofbauer cells contaminating the trophoblast cell preparations did
stain for each of these leukocyte receptors, providing a clear posi-
tive control for these assays. In Suppl Fig. 3, the Hofbauer cells are
EGF-R- and HLA-G-, their identiﬁcation by triple labelling as CD45þ
is not shown. Trophoblast also did not label for LAIR-1 in immuno-
histological staining of a ﬁrst trimester implantation site (Suppl
Fig. 3C). The left panel shows an anchoring column of trophoblast
derived from the villous placenta in cross section, with the distal
trophoblast identiﬁed as EVT by HLA-G labelling. None of the
trophoblast column labels for LAIR-1, ruling out intra-cellular
protein expression.
3.6. Trophoblast up-regulate the IL-2 receptor b subunit on
differentiation to an extravillous phenotype
IL-2 receptor b was the most highly up-regulated surface
receptor in EVTcompared to VT (Fig. 3).We conﬁrmedweak surface
expression of IL2Rb protein on VT but strong up-regulation on
differentiation to EVT by ﬂow cytometry of isolated cells and by
histology in vivo (Fig. 4). IL2Rb is a subunit in the receptor complex
of IL-2 and IL-15, but only the latter has been found in the decidua
[24]. The IL-15 receptor complex also includes IL-15Ra and
common g chain subunits but these were not detected on
trophoblast (Fig. 4A). The IL-15Ra mAb did bind peripheral blood
HLA-DRþ cells and the common g chain mAb bound YT cells in
control experiments (not shown).
R. Apps et al. / Placenta 32 (2011) 33e43403.7. Extravillous trophoblast secrete LAIR-2, soluble antagonist of
the LAIR-1 receptor expressed by peripheral and decidual leukocytes
LAIR-2, a soluble antagonist of the LAIR-1 receptor was in the top
20 of all transcripts up-regulated in EVT compared to VT (33 fold
higher, Suppl Table 3). EVT did label for LAIR-2 in immuno-histo-
logical staining of ﬁrst trimester implantation site (Fig. 5A). By
ELISA we detected LAIR-2 in the supernatants of isolated ﬁrst
trimester trophoblast cells (cultures were 70% HLA-Gþ), but not in
supernatants of villous mesenchyme or decidual stromal cells from
the same pregnancies (Fig. 5B). LAIR-2 protein is present in the
urine of pregnant, but not non-pregnant women [18] and serial
samples from two pregnant women showed that LAIR-2 levels in
urine are highest early in gestation (Fig. 5C,D). LAIR-2 was the most
down-regulated gene in a recent microarray study comparing ﬁrst
trimester chorionic villous samples fromnormal womenwith those
who went on to develop pre-eclampsia [25]. We therefore
compared LAIR-2 levels in the urine of gestationally-matched
donors from healthy and pre-eclamptic pregnancies collected at
between 10 and 16 weeks of gestation, but found no differences
(Fig. 5E). Nonetheless, these data do strongly suggest that EVT
secrete LAIR-2 as they invade into the decidua.
LAIR-2 has been shown to be a soluble antagonist of the closely
related LAIR-1 receptor that is expressed by all peripheral leukocytes
[26,27]. Using ﬂow cytometry of ﬁrst trimester decidual leukocytes,
we found that LAIR-1 is expressed by all CD3þ and HLA-DRþ cells,
and w50% of the CD56 þ cell population (Fig. 6A). Immuno-histo-
logical staining of the decidua basalis showed that these LAIR-1þ
leukocytes are present underlying glandular epithelium and around
blood vessels as well as scattered throughout the decidua (Fig. 6B).
4. Discussion
Our transcriptional analysis of villous and extravillous tropho-
blast cells isolated directly from the ﬁrst trimester implantation site
has reassuringly identiﬁed many genes previously known to be
differentially expressed in these two cell types. Genes more highly
expressed in EVT are CD9 [28] and CD155 [8], pregnancy-associated
plasma protein A [29], matrix metallopeptidases such as MMP-9,
laeverin and ADAM19 as well as their tissue inhibitor TIMP-2
[30e32]. Transcripts increased in VT include CD46 [33], PEG3 [34],
placental collectin 12 [35], PLAC8 [36], ferroportin-1 (SLC40A1) [37],
folate receptor 1 (FOLR1) [38], SIGLEC6 [39] and the transcription
factor ELF5 [40]. Further genes such as CD274 [41], glucose trans-
porter GLUT-1 [42], calcium uptake molecules TPT1 [43] and S100P
[44], and the thrombin receptor F2R [45] were detected in both
trophoblast cell types as has been reported before. Agreement with
these earlier ﬁndings gives conﬁdence that the many newgenes we
found expressed by trophoblast sub-populations will provide valid
and interesting leads for future functional studies.
A similar recent microarray study which sought to compare VT
and EVT identiﬁed the heme-oxygenase 1 pathway as down-
regulated in invasive EVT [46]. Apart from a more comprehensive
probe set, a major difference between this study and our own is that
we isolated trophoblast cells with minimal in vitro culture. VT was
used immediately and EVT after only 12 h culture. This compares
with 1 day (VT) and 3 days (EVT) of culture in the previous study.
Our aim was to reduce to a minimum the transcriptional changes
occurring ex vivo. In the previous study Bilban et al obtained VT by
HLA class I negative selection with magnetic beads and EVT by
manual picking of outgrowths from 3-day cultures of villous
explants. The purity of our ﬂow-sorted trophoblast populations is
higher (>99%) and these methodological differences as well as the
extent of differentiation into EVT may explain why our results are
different. Although we replicate many of the ﬁndings by Bilban etal, the magnitude of the differences between VT and EVT tend to be
much higher in the present study. HLA-G, ADAM-19 and PAPPA are
more than 60-fold higher in EVT compared to VT, but only 3-fold in
the earlier study. The analysis presented here also identiﬁes 3433
transcripts showing at least a two-fold difference between EVT and
VT, compared to 991 in the previous study.
JEG-3 and JAR are choriocarcinoma cell lines widely used as
models of primary EVT and VT respectively, but the expression
proﬁles of these choriocarcinoma cell lines very poorly repre-
sented the primary trophoblast. Syncytin (ERVWE1) was one of
only three transcripts up-regulated in both JAR and VT, compared
to JEG-3 and EVT, indicating JAR may be of use to study the role of
this endogenous retroviral molecule in fusion of the syncytial
villous trophoblast layer [47]. HLA-G was up-regulated in JEG-3
and EVT and this line has already been recognized as useful for
study of EVT HLA class I molecules [48]. The choriocarcinoma lines
are therefore of use to study some limited aspects of trophoblast
immunobiology, but transformation in vivo and their subsequent
culture have resulted in transcriptional proﬁles that are poorly
representative of primary trophoblast. Indeed JEG-3 was derived
from the cerebral metastasis of a choriocarcinoma in 1959, and has
subsequently been cultured for hundreds of passages in hamster
cheek pouches and laboratory tissue culture. It may be possible to
establish culture conditions in which the cell lines represent
primary trophoblast more closely, but these microarray proﬁles
suggest any phenotypic or functional analysis performed on the
lines must be validated in primary cells. For example, although
JEG-3 does express the non-classical HLA-G molecule, its confor-
mation on the surface of JEG-3 differs from that on primary EVT in
a manner that has functional consequences [49]. A recent analysis
of choriocarcinoma and placental cell lines transformed in vitro
supports this conclusion [57].
Comparison of the expression proﬁles of EVT and VT identiﬁed
3471 probes with signiﬁcantly different expression. To help
understand the biological processes they represented, these tran-
scripts were classiﬁed into functional categories based on either GO
annotation or KEGG pathways. Although functions such as cell
motion and immune response were previously known in EVT, this
revealed a much more complete picture of the transcripts involved.
An example is FAK, which has previously been studied in tropho-
blast invasion [50], but the signiﬁcant up-regulation of more than
40 transcripts involved in the focal adhesion and ECM-receptor
pathways gives a more complete understanding. This new global
analysis shows that many pathways are co-ordinately regulated. It
also identiﬁes many new transcripts in these pathways where
changes in expression may alter trophoblast function. The co-
ordinated changes in pathways lead us to examine what tran-
scription factors altered during the transition from VT to EVT. VT is
characterised by high expression of six transcription factors
expressed at 20e55 fold higher than in EVT. Differentiation to EVT
is associated with down-regulation of these, and up-regulation of
STAT4, IRF9 and STAT1 (>10 fold). We speculate that changes in
transcription factors such as STAT4 may serve to co-ordinate many
of the other gene expression changes that we document. In support
of this, the promoters of many of the genes most highly up-regu-
lated in EVT are predicted to contain STAT4 response elements.
These include STAT1, ETS1, CTGF, and ESAM, suggesting STAT4 may
act as a ‘master regulator’ of EVT differentiation.
Some of these genes identiﬁed might also serve as newmarkers
of trophoblast subsets. The microarray hybridization signal for
EGF-R, used here and in other studies to isolate VT, is only 5 fold
higher in VT than EVT. In contrast, the surface protein semaphorin
6A is more than 50-fold higher in VT than EVT, with SEMA6A
transcript levels 10 times higher in VT than EGF-R. We also found
high levels of expression in both VT and EVT of speciﬁc IgSF genes
Fig. 6. LAIR-1 expression in the decidua. Decidual leukocytes isolated from ﬁrst trimester pregnancies were analysed by surface ﬂow cytometry (A). The scatter gate R1 was used for
CD45, CD56 and CD3 positive cells and R2 for HLA-DRþmyelomonocytic cells. Histograms show isotype control and LAIR-1 mAb staining to the leukocyte population discriminated
(R3). Staining is representative of decidual leukocytes from 3 independent individuals. Histological staining of decidua adjacent to a ﬁrst trimester implantation site is shown (B). No
staining with an HLA-G mAb indicates the absence of extravillous trophoblast in this area. Immunoreactivity corresponding to LAIR-1 can be seen on maternal cells adjacent to
arteries and glands or scattered throughout the decidua (right), consistent with LAIR-1 expression by maternal leukocytes. SA, spiral artery; G, uterine gland.
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LAIR-1. These molecules are usually expressed by leukocytes and
indeed no protein expression was detected by ﬂow cytometry or
immunohistochemistry, despite high transcript levels they appear
not to be translated in trophoblast. In contrast, increased IL-2Rb
transcripts in EVT were conﬁrmed at the protein level by ﬂow
cytometry and immunohistology. There was no evidence of
expression of the common g chain or IL-15Ra, raising the question
of whether the IL-2 receptor b subunit alone could be functional.
When transfected alone, IL-2Rb forms a homodimer able to bind IL-
2 [51]. Complexes of IL-2Rb, formed by the intra-cellular domain of
IL-2Rb fused to the extracellular domain of c-kit, have been shown
to activate the Jak2 pathway [52] whereas IL-2 receptor signalling
through the conventional a/b/g complex leads to phosphorylation
of Jak1 and 3. Similar experiments have not been performed with
IL-15, which is synthesized by decidual cells and thus more likely
than IL-2 to stimulate the trophoblast IL-2Rb in vivo. Alternatively,
IL-2Rb may be involved in signalling through an as yet undiscov-
ered receptor complex.
An important aim of this study was to identify novel ways in
whichEVTmight interactwithdecidual leukocytes. IL-32mRNAwas
up-regulated in EVT and is known to be secreted by epithelial cells
following stimulation by IFN-g. IL-32 can stimulate its own release
fromNK cells in a feedback loop and potently induces macrophages
to secrete TNF-a and IL-8 [53]. This suggests EVT can regulate the
function of uNK cells andmacrophages by secretion of cytokines. NK
cell function is also controlled byactivating and inhibitory receptors,
which recognise MHC and non-MHC ligands in an immunological
synapse when NK cells directly contact target cells [7]. Extravillous
trophoblast is known toexpressHLA-G,HLA-C,HLA-E andnon-MHC
ligands such as E-cadherin, PVR and CD112 [2,8]. We also demon-
strate here high expression in both VT and EVT of transcripts of
CLEC2D (LLT-1 or OCIL), ligand for the activating NK cell receptor
CD161 (NKR-P1A). CLEC1A, an orphan receptor from the same family
was also highly expressed. Although these results require validation
at the protein level, they reveal new potential ligand/receptor
interactions between EVT and NK cells during placentation.
Another mechanism by which EVT may regulate the function of
decidual leukocytes is the apparent secretion of LAIR-2 by EVT.
Protein expression of LAIR-2 by EVT was conﬁrmed by histological
staining of anchoring cytotrophoblast columns, in agreement with
a recent study [54]. ELISA detected secreted LAIR-2 in trophoblast
culture supernatants and urine of pregnant women. LAIR-2 is
encoded adjacent to LAIR-1 in the LRC; LAIR-1 is an inhibitory
receptor binding to extracellular matrix collagen [27]. LAIR-2 is
a secreted protein with a single Ig-domain highly homologous to
that of LAIR-1, and it antagonises LAIR-1 binding to collagen [18].
LAIR-1 is expressed by almost all peripheral leukocytes [26] and we
show that it is expressed on at least 50% of decidual leukocytes.
Leukocytes in the systemic circulation are usually not exposed to
collagen but as they migrate from the blood, LAIR-1 binding to
collagen may deliver an inhibitory signal necessary in the decidual
microenvironment [27]. LAIR-2 secreted by invading EVT may
increase decidual leukocyte responsiveness by blocking LAIR-1
binding speciﬁcally at the maternalefetal interface, where
maternal leukocytes contact allogeneic fetal EVT. Alternatively
recent ﬁndings suggest LAIR-2 may have a role in local inhibition of
platelet activation and aggregation [56]. A potential role of LAIR-2
in trophoblast invasion is clearly suggested by a microarray study
comparing gene expression in chorionic villous samples of normal
ﬁrst trimester pregnancies with those that subsequently developed
pre-eclampsia [25], a disease caused by inadequate trophoblast
invasion [55]. LAIR-2 was the most down-regulated gene in
placentas fromwomen that went on to develop pre-eclampsia later
in pregnancy. We failed to ﬁnd any differences in urinary LAIR-2between normal and pre-eclamptic pregnancies from samples
taken early in pregnancy. These results suggest a novel mechanism
by which EVT may regulate the function of leukocytes locally in the
decidua, as well as the wider maternal immune system. Further
work is clearly warranted to characterise the functions of LAIR-1
and trophoblast LAIR-2 binding to extracellular matrix collagens at
the implantation site.
In summary, we provide a detailed analysis of the transcriptional
changes associatedwith the differentiation of villous to extravillous
trophoblast. Using highly puriﬁed primary trophoblast cells, we
identiﬁed over 3000 transcripts that are differentially expressed
between these trophoblast subsets. Many of the new genes that are
altered identify novel pathways that change, or add new players to
previously studied functions such as migration or immune modu-
lation. The differentiation from VT to EVT is characterised by alter-
ations in transcription factors, with STAT4 up-regulation identiﬁed
as a likely key regulator orchestrating these changes. We show that
EVTsecretes LAIR-2, amolecule that can regulate the functionsof the
inhibitory receptor LAIR-1 expressed on decidual T cells, macro-
phages and NK cells. As LAIR-2 is also detectable in urine from
pregnant women, trophoblast-derived LAIR-2 may also have wider
systemic effects during early pregnancy.
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